The combined efforts of researchers, investors, and pharmaceutical and biotech companies have resulted in substantial progress in the treatment of major diseases such as cancer, diabetes, a
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh